Quality of Reporting of Serious Adverse Drug Events to an Institutional Review Board: A Case Study with the Novel Cancer Agent, lmatinib Mesylate

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2009, Vol.15 (11), p.3850-3855
Main Authors: DORR, David A, BURDON, Rachel, BOYLE, Simone, TALLMAN, Martin S, TALPAZ, Moshe, SARTOR, Oliver, BENNETT, Charles L, WEST, Dennis P, LAGMAN, Jennifer, GEORGOPOULOS, Christina, BELKNAP, Steven M, MCKOY, June M, DJULBEGOVIC, Benjamin, EDWARDS, Beatrice J, WEITZMAN, Sigmund A
Format: Article
Language:English
Subjects:
Antineoplastic agents
Biological and medical sciences
Medical sciences
Pharmacology. Drug treatments
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:1078-0432
1557-3265